Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz.
Boolean network
Reactome
biological pathway
constrained fuzzy logic modeling
drug interaction visualization
functional interaction network
systems pharmacology
targeted therapy
Journal
F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
11
06
2019
entrez:
3
8
2019
pubmed:
3
8
2019
medline:
2
6
2020
Statut:
epublish
Résumé
The precision medicine paradigm is centered on therapies targeted to particular molecular entities that will elicit an anticipated and controlled therapeutic response. However, genetic alterations in the drug targets themselves or in genes whose products interact with the targets can affect how well a drug actually works for an individual patient. To better understand the effects of targeted therapies in patients, we need software tools capable of simultaneously visualizing patient-specific variations and drug targets in their biological context. This context can be provided using pathways, which are process-oriented representations of biological reactions, or biological networks, which represent pathway-spanning interactions among genes, proteins, and other biological entities. To address this need, we have recently enhanced the Reactome Cytoscape app, ReactomeFIViz, to assist researchers in visualizing and modeling drug and target interactions. ReactomeFIViz integrates drug-target interaction information with high quality manually curated pathways and a genome-wide human functional interaction network. Both the pathways and the functional interaction network are provided by Reactome, the most comprehensive open source biological pathway knowledgebase. We describe several examples demonstrating the application of these new features to the visualization of drugs in the contexts of pathways and networks. Complementing previous features in ReactomeFIViz, these new features enable researchers to ask focused questions about targeted therapies, such as drug sensitivity for patients with different mutation profiles, using a pathway or network perspective.
Identifiants
pubmed: 31372215
doi: 10.12688/f1000research.19592.1
pmc: PMC6644836
doi:
Substances chimiques
Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
908Subventions
Organisme : NHGRI NIH HHS
ID : P41 HG003751
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA239069
Pays : United States
Organisme : NHGRI NIH HHS
ID : U41 HG003751
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224019
Pays : United States
Déclaration de conflit d'intérêts
No competing interests were disclosed.
Références
Biotechnol J. 2012 Mar;7(3):374-86
pubmed: 22125256
F1000Res. 2014 Jul 01;3:146
pubmed: 25309732
Brief Bioinform. 2016 Jan;17(1):2-12
pubmed: 25832646
Phys Biol. 2012 Aug;9(4):045003
pubmed: 22871648
Science. 2008 Jul 11;321(5886):263-6
pubmed: 18621671
Nat Biotechnol. 2008 Jan;26(1):127-32
pubmed: 18183025
Nucleic Acids Res. 2016 Jan 4;44(D1):D1045-53
pubmed: 26481362
Sci Rep. 2017 Oct 6;7(1):12771
pubmed: 28986545
Genome Biol. 2007;8(3):R39
pubmed: 17367534
J R Soc Interface. 2008 Aug 6;5 Suppl 1:S85-94
pubmed: 18508746
Eur J Pharmacol. 2006 Mar 8;533(1-3):327-40
pubmed: 16483568
Expert Opin Ther Targets. 2012 Jan;16(1):15-31
pubmed: 22239438
Br J Cancer. 2011 Apr 12;104(8):1241-5
pubmed: 21364581
PLoS One. 2013 Jul 26;8(7):e69008
pubmed: 23922675
Brief Bioinform. 2018 Dec 18;:
pubmed: 30566623
PLoS Comput Biol. 2011 Mar;7(3):e1001099
pubmed: 21408212
Bioinformatics. 2010 Jun 15;26(12):i237-45
pubmed: 20529912
Nucleic Acids Res. 2015 Jan;43(2):e10
pubmed: 25392414
Nature. 2006 Jan 19;439(7074):353-7
pubmed: 16273092
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
PLoS Comput Biol. 2009 May;5(5):e1000387
pubmed: 19436720
Curr Cancer Drug Targets. 2006 Feb;6(1):65-75
pubmed: 16475976
Trends Pharmacol Sci. 2017 Dec;38(12):1085-1099
pubmed: 28964549
Nat Biotechnol. 2010 Sep;28(9):935-42
pubmed: 20829833
Nucleic Acids Res. 2014 Jan;42(Database issue):D1091-7
pubmed: 24203711
Trends Mol Med. 2017 Oct;23(10):874-898
pubmed: 28887051
Nat Rev Drug Discov. 2017 Jan;16(1):19-34
pubmed: 27910877
Nucleic Acids Res. 2011 Jan;39(Database issue):D712-7
pubmed: 21071422
Nat Rev Cancer. 2017 Oct 25;17(11):637-658
pubmed: 29068003
J Oncol. 2010;2010:568938
pubmed: 20037743
Nucleic Acids Res. 2014 Jan;42(Database issue):D1098-106
pubmed: 24234439
Future Med Chem. 2012 Mar;4(4):447-69
pubmed: 22416774
Nucleic Acids Res. 2016 Jan 4;44(D1):D481-7
pubmed: 26656494
Nucleic Acids Res. 2019 Jan 8;47(D1):D963-D970
pubmed: 30371892
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nat Biotechnol. 2006 Jul;24(7):805-15
pubmed: 16841068
Methods Mol Biol. 2009;563:123-40
pubmed: 19597783
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Methods Mol Biol. 2013;1015:311-20
pubmed: 23824865
Nat Rev Drug Discov. 2018 Jan;17(1):1-2
pubmed: 29170471
Genome Biol. 2010;11(5):R53
pubmed: 20482850
Nucleic Acids Res. 2017 Jan 4;45(D1):D932-D939
pubmed: 27789690
J Clin Oncol. 2013 Apr 20;31(12):1592-605
pubmed: 23509311
Nucleic Acids Res. 2016 Jan 4;44(D1):D1069-74
pubmed: 26578601
Cancer Metastasis Rev. 2017 Mar;36(1):91-108
pubmed: 28265786
Trends Pharmacol Sci. 2015 Jul;36(7):422-39
pubmed: 25975227
BMC Syst Biol. 2012 Oct 18;6:133
pubmed: 23079107
Biosystems. 2015 Mar;129:1-18
pubmed: 25637875
J Theor Biol. 1969 Mar;22(3):437-67
pubmed: 5803332